Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AxoGen, Inc. (NASDAQ: AXGN).

Full DD Report for AXGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: AXGN)

Institutional Top Ideas Series: Opaleye Management
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund we´ve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds ...
Source: SeekingAlpha
Date: May, 17 2018 01:52
AxoGen, Inc. Announces Closing of Public Offering of Common Stock
ALACHUA, Fla., May 14, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced the closing of its previously announced underwritten public offering of 3,450,000 shares of its common...
Source: GlobeNewswire
Date: May, 14 2018 07:00
AxoGen, Inc. Announces Upsizing and Pricing of Public Offering of Common Stock
ALACHUA, Fla., May 09, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced today that it has priced an underwritten public offering of 3,000,000 shares of its common stock, which was ...
Source: GlobeNewswire
Date: May, 09 2018 07:00
AxoGen, Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by AxoGen, Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 01 2018 13:24
AxoGen down 5% post Q1 results
AxoGen ( AXGN -4.8% ) reports Q1 revenue growth of 41% Y/Y to $17.26M. More news on: AxoGen, Inc., Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 01 2018 13:24
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2018 Results - Earnings Call Transcript
AxoGen, Inc. (AXGN) Q1 2018 Earnings Conference Call April 30, 2018 04:30 p.m. ET Executives Karen Zaderej - President, Chief Executive Officer Pete Mariani - Chief Financial Officer Brian Korb - Investor Relations Analysts Dave Turkaly - JMP Securities Richard Newitter -...
Source: SeekingAlpha
Date: April, 30 2018 22:33
AxoGen, Inc. Reports 2018 First Quarter Financial Results
ALACHUA, Fla., April 30, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today reported financial results and business highlights for the first quarter ended March 31, 2018. First Quart...
Source: GlobeNewswire
Date: April, 30 2018 16:05
Notable earnings after Monday's close
AEIS , AKAM , ALSN , APPF , APTI , APTS , ARE , AXGN , BFAM , BLKB , BRX , CGNX , EFII , EGOV , FET , GPT , HLIT , HSTM , HTLF , IDTI , INGN , INST , JJSF , KAI , KWR , MEDP , MPWR , MTZ , MX , NBIX , NTRI , OFIX , OGS , PKI , QTNA , RCII , REG , RIG , ...
Source: SeekingAlpha
Date: April, 29 2018 17:35
AxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018
ALACHUA, Fla., April 18, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that it will report first quarter 2018 financial results on Monday, April 30, 2018 after the market ...
Source: GlobeNewswire
Date: April, 18 2018 07:00
AxoGen Offers An Exciting Story At Nosebleed Prices
When the stocks of real companies go up more than 250% in a year, it’s a safe bet that there are at least two factors in play – the company has a great growth story and institutions have caught wind of it. And so it would seem with AxoGen ( AXGN ), where the company’s pr...
Source: SeekingAlpha
Date: April, 12 2018 08:27

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1744.0042.4544.400342.30362,563
2017-06-2015.1515.2515.6515.133132,876
2017-06-1914.7515.1515.2014.70164,562
2017-06-1614.5514.7514.8514.25222,858
2017-06-1514.8014.6514.8514.60104,631

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17123,344168,51873.1934Short
2018-08-1680,352418,88319.1824Cover
2018-08-1587,852127,44368.9343Short
2018-08-14112,864221,13251.0392Short
2018-08-13104,509162,12164.4636Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AXGN.


About AxoGen, Inc. (NASDAQ: AXGN)

Logo for AxoGen, Inc. (NASDAQ: AXGN)

AxoGen OTCBB: AXGN is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen s products offer a full suite of surgical nerve reconstruction solutions including Avance Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.

 

 

 

Current Management

  • Karen Zaderej / CEO
  • Gregory G. Freitag / CFO, General Counsel
  • Jamie M. Grooms / Chairman
  • Gregory G. Freitag /
  • John Harper /
  • Mark Gold M.D. /
  • Joe Mandato /
  • John McLaughlin /
  • Robert J. Rudelius /
  • Karen Zaderej /

Current Share Structure

  • Market Cap: $1,538,145,370 - 05/14/2018
  • Authorized: 50,000,000 - 12/15/2012
  • Issue and Outstanding: 34,681,970 - 04/27/2018

 


Recent Filings from (NASDAQ: AXGN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 10 2018
Automatic shelf registration statement of securities of well-known seasoned issuers
Filing Type: S-3ASRFiling Source: edgar
Filing Date: May, 07 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 07 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 30 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 30 2018

 

 


Daily Technical Chart for (NASDAQ: AXGN)

Daily Technical Chart for (NASDAQ: AXGN)


Stay tuned for daily updates and more on (NASDAQ: AXGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AXGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AXGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AXGN and does not buy, sell, or trade any shares of AXGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/